Characteristics of 39 patients with idiopathic CD4 lymphocytopenia
| Characteristic/category . | No (%) . |
|---|---|
| Sex | |
| Male | 17 (43.6) |
| Female | 22 (56.4) |
| Race | |
| White | 35 (89.7) |
| Black | 2 (5.1) |
| Asian | 2 (5.1) |
| Age, y (range) | |
| 20 to 30 | 2 (5.1) |
| 30 to 40 | 12 (30.8) |
| 40 to 50 | 17 (43.6) |
| 50 to 60 | 4 (10.3) |
| 60 to 70 | 2 (5.1) |
| 70 to 80 | 0 |
| 80 to 90 | 2 (5.1) |
| OI at diagnosis | |
| Cryptococcosis | 13 (33.3) |
| Human papillomavirus infection | 8 (20.5) |
| Nontuberculous mycobacteria | 4 (10.3) |
| Histoplasmosis | 2 (5.1) |
| Mucosal candidiasis | 2 (5.1) |
| Dermatomal varicella zoster virus infection | 1 (2.6) |
| Pneumocystis jirovecii pneumonia | 1 (2.6) |
| Cytomegalovirus pneumonia | 1 (2.6) |
| No infection | 7 (17.9) |
| OI (episodes) in follow-up | |
| Human papillomavirus infection | 6 (15.4) |
| Mucosal candidiasis | 4 (10.3) |
| Dermatomal varicella zoster virus infection | 4 (10.3) |
| Nontuberculous mycobacteria | 2 (5.1) |
| P jirovecii pneumonia | 1 (2.6) |
| EBV lymphoproliferative disease | 1 (2.6) |
| Molluscum contagiosum | 1 (2.6) |
| Progressive multifocal leucoencephalopathy | 1 (2.6) |
| Any infection in follow-up | 15 (38.5) |
| No infection in follow-up | 21 (53.8) |
| No follow-up | 3 (7.7) |
| Median follow-up, mo (range) | 49.5 (0-204) |
| Characteristic/category . | No (%) . |
|---|---|
| Sex | |
| Male | 17 (43.6) |
| Female | 22 (56.4) |
| Race | |
| White | 35 (89.7) |
| Black | 2 (5.1) |
| Asian | 2 (5.1) |
| Age, y (range) | |
| 20 to 30 | 2 (5.1) |
| 30 to 40 | 12 (30.8) |
| 40 to 50 | 17 (43.6) |
| 50 to 60 | 4 (10.3) |
| 60 to 70 | 2 (5.1) |
| 70 to 80 | 0 |
| 80 to 90 | 2 (5.1) |
| OI at diagnosis | |
| Cryptococcosis | 13 (33.3) |
| Human papillomavirus infection | 8 (20.5) |
| Nontuberculous mycobacteria | 4 (10.3) |
| Histoplasmosis | 2 (5.1) |
| Mucosal candidiasis | 2 (5.1) |
| Dermatomal varicella zoster virus infection | 1 (2.6) |
| Pneumocystis jirovecii pneumonia | 1 (2.6) |
| Cytomegalovirus pneumonia | 1 (2.6) |
| No infection | 7 (17.9) |
| OI (episodes) in follow-up | |
| Human papillomavirus infection | 6 (15.4) |
| Mucosal candidiasis | 4 (10.3) |
| Dermatomal varicella zoster virus infection | 4 (10.3) |
| Nontuberculous mycobacteria | 2 (5.1) |
| P jirovecii pneumonia | 1 (2.6) |
| EBV lymphoproliferative disease | 1 (2.6) |
| Molluscum contagiosum | 1 (2.6) |
| Progressive multifocal leucoencephalopathy | 1 (2.6) |
| Any infection in follow-up | 15 (38.5) |
| No infection in follow-up | 21 (53.8) |
| No follow-up | 3 (7.7) |
| Median follow-up, mo (range) | 49.5 (0-204) |
OI indicates opportunistic infection; and EBV, Epstein-Barr virus.